Jazz Pharmaceuticals announced it has successfully completed the acquisition of the privately-held Actio Biosciences for an $820 million upfront payment. The transaction makes Actio a wholly-owned subsidiary of Jazz and significantly strengthens its rare disease and epilepsy pipeline.
Key Details
- Transaction Value: Jazz acquired Actio Biosciences for an upfront payment of $820 million.
- Strategic Asset: The acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy.
- Pipeline Expansion: The deal strengthens Jazz's epilepsy portfolio and reinforces its strategic focus on advancing treatments for rare diseases.
- Regulatory Status: The acquired drug candidate, ABS-1230, has received Fast Track, Rare Pediatric Disease, and Orphan Drug Product designations from the U.S. Food and Drug Administration (FDA).